ESMO guidelines currently recommend testing at least EGFR mutations, BRAF mutations, ALK fusions, ROS-1 fusions, MET exon 14 skipping mutations, RET rearrangements and PD-L1 expression levels in non-squamous advanced NSCLC [54]. This evidence concerns the gene ALK and non-small cell lung carcinoma.